Tilray Inc. (TLRY) saw its stock surge 6.46% in after-hours trading following the release of its second-quarter earnings report, which exceeded analyst expectations on both revenue and earnings per share.
The company reported quarterly earnings of $0.01 per share, significantly beating the consensus estimate of a $0.20 loss. Revenue also surpassed forecasts, coming in at $217.5 million compared to the expected $210.95 million. This performance was driven by a 36% increase in international medical cannabis revenue and a 6% rise in Canadian adult-use cannabis sales.
CEO Irwin D. Simon highlighted the company's disciplined execution and diversified portfolio, which includes cannabis, beverage, wellness, and distribution sectors. He also emphasized Tilray's readiness to expand into the U.S. medical cannabis market as regulatory conditions evolve, further boosting investor confidence.
Comments